Thus, NZ, by reducing IL-6 s and completely abolishing CCL5 secretion by MSCs may counteract the consequences of MSCs/PCa [8, 13, 25, 46, 50, 51] and MSCs/breast cancer [49, 52, 53] interactions. The gene discussed is CCL5; the disease is posterior cortical atrophy.